These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30609341)

  • 1. [Direct Oral Anticoagulants (DOACs): Pharmacological Characteristics and Laboratory Assessment].
    Kitajima I
    Rinsho Byori; 2016 Aug; 64(8):972-979. PubMed ID: 30609341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
    Lippi G; Favaloro EJ
    Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.
    Favaloro EJ; Pasalic L; Curnow J; Lippi G
    Curr Drug Metab; 2017; 18(7):598-608. PubMed ID: 28413976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulants (DOACs): From the laboratory point of view.
    Margetić S; Goreta SŠ; Ćelap I; Razum M
    Acta Pharm; 2022 Dec; 72(4):459-482. PubMed ID: 36651369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
    Adcock DM; Gosselin R
    Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
    Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
    J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.
    Conway SE; Hwang AY; Ponte CD; Gums JG
    Pharmacotherapy; 2017 Feb; 37(2):236-248. PubMed ID: 27983747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review.
    Di Minno A; Spadarella G; Prisco D; Franchini M; Lupoli R; Di Minno MN
    Semin Thromb Hemost; 2013 Oct; 39(7):840-6. PubMed ID: 24022805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.
    Samuelson BT; Cuker A; Siegal DM; Crowther M; Garcia DA
    Chest; 2017 Jan; 151(1):127-138. PubMed ID: 27637548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
    Papadaki S; Tselepis AD
    Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.